The future of generic medicine business models in brazil and pharmaceutical industries.

Abstract

What is the probable scenario and how the pharmaceutical industry will be impacted by generic medicines, until the year 2030? This article seeks to organize different international and national studies, and within the international section there is a division between productions aimed at the market, the regulatory issue or public policies, in addition to standards, which stand out among the topics most addressed by international studies of according to a survey on the Web of Science). In order to compose the 2030 scenario, the study counted on the contribution of 10 pharmaceutical specialists (executives and academics).